In immuno-oncology, biomarkers are widely used to guide clinical trial programs, help researchers better understand the mechanism of action of their drugs and ultimately give predictive information of drug response or toxicity. However, the complexity associated with drugs’ mechanism of action and the dynamics of the immune response makes it challenging to analyze biomarkers and extract meaningful insights. It is, therefore, critical to create rich biological databases to reinforce and validate biologic hypotheses, de-risk clinical trial failure and efficiently identify predictive biomarkers. Incorporating a multiomics analysis can shed light on disease pathways and other complex mechanisms.
Immunotherapy has emerged as the most promising cancer treatment in the last decade with a major impact in oncology by inducing durable responses. However, until now, relatively few patients have been able to benefit from this advance. With a growing number of clinical trials testing immune checkpoint inhibitors (ICI) or CAR T therapies, one of the main objectives for researchers now is to extend immunotherapeutic approaches to more patients and tumor types while decreasing the risk of clinical trial failures.
During this webinar, featured speakers will introduce a reference database in diffuse large B cell lymphoma (DLBCL), a type of non-Hodgkin lymphoma. The ambitious program assesses thousands of parameters using an unsupervised multiomic and multimodal approach. The database may be used to generate maps and clusters that can be used for patient group identification and clinical outcome interpretation.
Register to gain valuable insights about a tumor microenvironment-based multiomics analysis for predictive modelling in biopharma.
Mike Mattie, PhD, Director of Translational Sciences and External Collaborations, Kite - a Gilead Company
Dr. Mike Mattie joined Kite in 2017 and leads a portfolio of research programs with academic collaborators and CROs aimed at strengthening the understanding of Kite products and leadership in the field of cell therapy. In addition, he leads internal bed to bench efforts to translate insights from Kite clinical trial specimens and mechanistic studies to inform research, clinical and process development efforts. Mike earned his PhD from Duke University and completed postdoctoral training at the UCSF Comprehensive Cancer Center. He brings nearly two decades of pharmaceutical industry experience having worked at GlaxoSmithKline and Agensys/Astellas Pharma working on small molecule, RNA therapeutics and antibody drugs prior to joining Kite.
Jérôme Galon, PhD, Senior Vice President and Scientific Executive Director, Veracyte
Jérôme Galon is Director of Research at INSERM (French NIH) and Head of the Laboratory of Integrative Cancer Immunology in Paris, France. He is also Associate Director and Co-Founder of the European Academy of Tumor Immunology (EATI), board member of the Society for Immunotherapy of Cancer (SITC) and Senior Vice President and Scientific Executive Director at Veracyte. His work on the comprehensive analysis of the tumor microenvironment led to the concept of cancer immune contexture.
Jérôme Galon pioneered Immunoscore and is the Principal Investigator of the Worldwide Immunoscore Consortium. He has been a consultant and/or served on the scientific advisory board of 28 biotech and pharmaceutical companies. His contributions have been recognized with numerous awards, including the William B Coley Award, USA (2010), the prestigious European Patent Office (EPO, EU) as European Inventor 2019 for Immunoscore®, the Senior Research Prize Jean Valade from the Fondation de France (2020) and on January 1st 2020, he was appointed Knight of the Legion of Honour by presidential decree.
Who Should Attend?
Biopharma teams involved in immuno-oncology with responsibilities including, but not limited to:
- Biomarker Discovery
- Translational Medicine
- Clinical Development
- CDx Development
What You Will Learn
Attendees will learn:
- How a comprehensive cancer reference database can help biopharma in their clinical programs
- How Veracyte partners with biopharma companies to build a customized database
Veracyte is a pioneering, global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions. Our growing menu of advanced diagnostic tests help patients avoid risky, costly procedures and interventions, and accelerate time to appropriate treatment. Veracyte offers customized multi-omics tools and expertise to our biopharmaceutical partners, helping them advance their therapeutic discovery, development, and commercialization programs.